HBM Healthcare Investments AG Stock
Equities
HBMN
CH0012627250
Investment Management & Fund Operators
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 206.50 CHF | -0.24% |
|
-0.72% | +17.33% |
| Dec. 08 | HBM Healthcare Investments Set to Receive Payments from Portfolio Company Sale | MT |
| Dec. 08 | Mirum Pharmaceuticals to acquire HBM portfolio company Bluejay Therapeutics | RE |
| Capitalization | 1.38B 1.71B 1.47B 1.29B 2.37B 154B 2.57B 16B 6.22B 72.88B 6.42B 6.29B 269B | P/E ratio 2026 * |
169x | P/E ratio 2027 * | 12.9x |
|---|---|---|---|---|---|
| Enterprise value | 1.38B 1.71B 1.47B 1.28B 2.36B 154B 2.57B 15.97B 6.21B 72.78B 6.41B 6.28B 268B | EV / Sales 2026 * |
39.2x | EV / Sales 2027 * | 10.1x |
| Free-Float |
80.6% | Yield 2026 * |
3.69% | Yield 2027 * | 3.57% |
| 1 day | -0.24% | ||
| 1 week | -0.72% | ||
| Current month | -0.72% | ||
| 1 month | +6.44% | ||
| 3 months | +16.67% | ||
| 6 months | +16.67% | ||
| Current year | +17.33% |
| 1 week | 203.5 |  | 209 |
| 1 month | 194.2 | | 209 |
| Current year | 150 | | 209 |
| 1 year | 150 | | 209 |
| 3 years | 135.2 | | 233 |
| 5 years | 135.2 | | 367 |
| 10 years | 91.4 | | 367 |
| Manager | Title | Age | Since |
|---|---|---|---|
Andreas Wicki
CEO | Chief Executive Officer | 66 | 2012-02-19 |
Erwin Troxler
DFI | Director of Finance/CFO | 55 | 2011-10-31 |
Benedikt Suter
SEC | Corporate Secretary | 61 | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 69 | 2009-05-31 | |
Rudolf Lanz
BRD | Director/Board Member | 75 | 2002-12-31 |
Mario Giuliani
BRD | Director/Board Member | 53 | 2011-12-31 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.24% | -0.72% | +11.26% | -11.18% | 1.71B | |
| -0.32% | +2.99% | -2.42% | +39.12% | 3.41B | |
| -0.17% | +4.44% | +53.41% | +28.88% | 1.13B | |
| 0.00% | -1.70% | +2.21% | -2.73% | 644M | |
| 0.00% | 0.00% | -44.82% | -71.35% | 537M | |
| +0.60% | +3.82% | -13.65% | -1.47% | 517M | |
| -1.99% | -4.13% | +2.20% | +86.30% | 427M | |
| -2.31% | +7.41% | +135.50% | +126.31% | 376M | |
| -2.27% | 0.00% | -4.44% | -10.79% | 349M | |
| +1.36% | +1.36% | -1.97% | -0.67% | 347M | |
| Average | -0.53% | +1.20% | +13.73% | +18.24% | 944.59M | |
| Weighted average by Cap. | -0.36% | +1.90% | +9.67% | +19.72% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 35.1M 43.54M 37.41M 32.71M 60.23M 3.91B 65.46M 407M 158M 1.85B 163M 160M 6.83B | 134M 167M 143M 125M 231M 14.98B 251M 1.56B 606M 7.1B 626M 612M 26.16B |
| Net income | 10.2M 12.65M 10.87M 9.5M 17.5M 1.14B 19.02M 118M 45.97M 539M 47.49M 46.48M 1.99B | 110M 136M 117M 102M 188M 12.21B 204M 1.27B 494M 5.79B 510M 499M 21.32B |
| Net Debt | -2M -2.48M -2.13M -1.86M -3.43M -223M -3.73M -23.19M -9.01M -106M -9.31M -9.11M -389M | -20M -24.81M -21.32M -18.64M -34.32M -2.23B -37.3M -232M -90.14M -1.06B -93.11M -91.14M -3.89B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-09 | 206.50 CHF | -0.24% | 3,522 |
| 25-12-08 | 207.00 CHF | +0.49% | 2,723 |
| 25-12-05 | 206.00 CHF | +0.24% | 4,904 |
| 25-12-04 | 205.50 CHF | 0.00% | 13,971 |
| 25-12-03 | 205.50 CHF | -1.20% | 5,895 |
Delayed Quote Swiss Exchange, December 09, 2025 at 11:31 am EST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Annual profits - Rate of surprise
- Stock Market
- Equities
- HBMN Stock
Select your edition
All financial news and data tailored to specific country editions
